<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308709</url>
  </required_header>
  <id_info>
    <org_study_id>472677</org_study_id>
    <secondary_id>CCRO030</secondary_id>
    <nct_id>NCT02308709</nct_id>
  </id_info>
  <brief_title>Novel Lung Functional Imaging for Personalized Radiotherapy</brief_title>
  <official_title>Novel Lung Functional Imaging for Personalized Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and feasibility of personalized&#xD;
      radiotherapy with four-dimensional (4D) computed tomography (CT)-based pulmonary ventilation&#xD;
      imaging, which selectively avoids irradiating highly-functional lung regions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical trial, the investigators will assess the safety and feasibility of 4D CT&#xD;
      ventilation image-guided personalized radiotherapy. The investigators will deliver&#xD;
      personalized radiotherapy treatments that selectively avoid irradiating highly-functional&#xD;
      lung regions for lung cancer patients, and follow up patients to assess the safety and&#xD;
      feasibility. The primary hypothesis to be tested is: 4D CT ventilation image-guided&#xD;
      personalized radiotherapy can be delivered safely for lung cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 15, 2014</start_date>
  <completion_date type="Anticipated">November 19, 2021</completion_date>
  <primary_completion_date type="Actual">November 19, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade ≥3 AEs defined as definitely, probably, or possibly related to 4D CT ventilation image-guided personalized radiotherapy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiation pneumonitis graded by CTCAE v4.0</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment change in forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment change in diffusing capacity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Ventilation image-guided radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 4D CT ventilation image-guided personalized radiotherapy treatment that selectively avoids irradiating highly-functional lung regions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Ventilation image-guided radiotherapy</intervention_name>
    <description>Patient's treatment plan will be created and optimized to minimize the dose to highly-functional lung regions</description>
    <arm_group_label>Ventilation image-guided radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary lung cancer or metastatic disease to the lungs to be treated with either&#xD;
             conventionally-fractionated radiotherapy (CFRT) or hypo-fractionated stereotactic&#xD;
             ablative radiotherapy (SABR).&#xD;
&#xD;
          -  Age restriction and/or gender/ethnic restrictions: Patients must be ≥18 years of age.&#xD;
             There are no gender or ethnic restrictions.&#xD;
&#xD;
          -  Concurrent chemotherapy is allowed, but not required.&#xD;
&#xD;
          -  Life expectancy with treatment should be ≥6 months in the estimation of the treating&#xD;
             physicians.&#xD;
&#xD;
          -  Zubrod performance status ≤2&#xD;
&#xD;
          -  Adequate marrow and hepatic function defined as Hgb ≥8; platelets ≥100k; ANC≥1500;&#xD;
             LFTs ≤2x upper limit of normal and creatinine ≤1.3 or creatinine clearance of ≥50&#xD;
&#xD;
          -  Patient must be able to provide study specific informed consent prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior radiotherapy for thoracic cancer or other malignancy leading to any overlap of&#xD;
             planned radiotherapy fields.&#xD;
&#xD;
          -  For patients undergoing definitive CFRT, patients with distant metastatic disease are&#xD;
             not eligible.&#xD;
&#xD;
          -  For patients undergoing SABR, both early stage primary lung cancer patients and those&#xD;
             with limited metastatic disease to the lungs are eligible; however, patients with&#xD;
             oligometastatic disease should have a controlled primary and no more than one other&#xD;
             involved organ system.&#xD;
&#xD;
          -  Children (&lt;18 years of age), pregnant women, University of California employees or&#xD;
             students, or prisoners will be excluded from this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tokihiro Yamamoto, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Pulmonary Functional Imaging</keyword>
  <keyword>Computed Tomography (CT)</keyword>
  <keyword>Image Registration</keyword>
  <keyword>Functional Image-guided Radiotherapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

